|
注册号: Registration number: |
ChiCTR2300077506 |
|
最近更新日期: Date of Last Refreshed on: |
2024-06-03 09:38:18 |
|
注册时间: Date of Registration: |
2023-11-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
简短言语干预促进流感疫苗接种的机制、开发与验证研究 |
|
Public title: |
Mechanisms, Development, and Validation of Brief Verbal Intervention in Promoting Influenza Vaccination UpTake (BEAT Trial) |
|
注册题目简写: |
|
|
English Acronym: |
BEAT trial |
|
研究课题的正式科学名称: |
简短言语干预促进流感疫苗接种的机制、开发与验证研究 |
|
Scientific title: |
Mechanisms, Development, and Validation of Brief Verbal Intervention in Promoting Influenza Vaccination UpTake (BEAT Trial) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈晓珊 |
研究负责人: |
骆焕园 |
|
Applicant: |
Xiaoshan Chen |
Study leader: |
Huanyuan Luo |
|
申请注册联系人电话: Applicant telephone: |
+86 130 6694 8007 |
研究负责人电话:
Study leader's |
+86 182 1562 7985 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xiaoshanchen@i.smu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
huanyuanluo33@gmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市白云区沙太南路1023号 |
研究负责人通讯地址: |
广东省广州市越秀区麓景路2号 |
|
Applicant address: |
1023 Shatai Road South, Baiyun District, Guangzhou, Guangdong, China |
Study leader's address: |
2 Lujing Road, Yuexiu District, Guangzhou, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南方医科大学卫生管理学院 |
||
|
Applicant's institution: |
School of Health Management, Southern Medical University |
||
|
研究负责人所在单位: |
南方医科大学皮肤病医院 |
||
|
Affiliation of the Leader: |
Dermatology Hospital of Southern Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023154 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南方医科大学皮肤病医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Dermatology Hospital of Southern Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-11-07 00:00:00 | ||
|
伦理委员会联系人: |
吕萍 |
||
|
Contact Name of the ethic committee: |
Ping Lyu |
||
|
伦理委员会联系地址: |
广东省广州市越秀区麓景路7号老干大厦2楼 |
||
|
Contact Address of the ethic committee: |
2/F, Laogan Building, 7 Lujing Road, Yuexiu District, Guangzhou, Guangdong, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8302 7645 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
gdpfkjk@vip.163.com |
|
研究实施负责(组长)单位: |
南方医科大学皮肤病医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Dermatology Hospital of Southern Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市越秀区麓景路2号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2 Lujing Road, Yuexiu District, Guangzhou, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
瑞士发展与合作署 |
||||||||||||||||||||||
|
Source(s) of funding: |
Swiss Agency for Development and Cooperation |
||||||||||||||||||||||
|
研究疾病: |
流行性感冒 |
||||||||||||||||||||||
|
Target disease: |
influenza |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
开发和验证简短言语干预以提升流感疫苗接种率。具体为以下3个子目标: (1)探索我国影响流感疫苗接种的障碍因素; (2)针对障碍因素,开发简短言语干预以提升流感疫苗接种率; (3)验证简短言语干预提升流感疫苗接种率的效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
To develop and validate a brief speech intervention to enhance influenza vaccination rates. Specifically, the following 3 sub-objectives: (1) To explore the barriers to influenza vaccination in China; (2) To develop a brief speech intervention to enhance influenza vaccination rates by targeting the barrier factors; (3) To validate the effectiveness of a brief verbal intervention to increase influenza vaccination rates. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.对于医疗机构,排除标准为: (1)曾参与其他流感疫苗接种率提升相关研究的医疗机构; (2)医疗机构内仅有1名预防接种人员。 2.对于研究对象,排除标准为: (1)前往医疗机构接种流感疫苗的群众; (2)在当前流感流行季节已经接种过流感疫苗的群众。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. For medical institutions, the exclusion criteria will be: (1) Medical institutions that had participated in other studies related to the improvement of influenza vaccination rates; (2) Medical institutions with only one vaccinator in the medical institution. 2. For study participants, the exclusion criteria will be: (1) People who are going to medical institutions for influenza vaccination; (2) People who had already received influenza vaccination during the current influenza epidemic season. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-11-13 00:00:00至 To 2024-02-06 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-11-13 00:00:00 至 To 2024-01-06 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
医疗机构采取目的性抽样,每个城市在可协调的医疗机构中,在城市或农村地区分别抽取1个基层医疗机构,共抽取2家医疗机构; 干预执行者采取目的性抽样,每个医疗机构以干预执行者的工作年限为主要目的进行抽取,共抽取2名负责疫苗信息登记的医务人员且随机分为干预组和对照组; 研究对象入组采取随机抽样,由独立的统计学家生成随机列表,由研究者或指定授权人员按照随机列表将受试者分配到干预组和对照组中的一个,获取唯一的随机入组编号。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Healthcare facilities were sampled purposively, with 1 primary care facilities in each city among the coordinable healthcare facilities in either urban or rural areas, for a total of 2 healthcare facilities; Intervention implementers will be sampled purposively, with each medical institution sampled with the intervention implementer's years of experience as the main purpose, and a total of 2 medical personnel will be selected; Subject enrollment was by random sampling, where a random list was generated by an independent statistician, and a unique random enrollment number was obtained by the researcher or a designated authorized person who assigned subjects to one of the intervention and control groups according to the random list. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
由于干预措施的性质,受试者、医生知晓受试者被分配到的研究组,而研究负责人员、数据分析人员不知晓受试者被分配到的研究组。 |
|
Blinding: |
Due to the nature of the intervention, the subject, the physician, will be aware of the study group to which the subject was assigned, while the person in charge of the study and data analysts, will not be aware of the study group to which the subject will be assigned. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究数据采集结束后,经过一年的数据保护期,相关研究人员可根据合理需求向通讯作者索取原始数据。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After a one-year data protection period at the end of the study data collection, the researchers concerned may request the original data from the corresponding authors according to their reasonable needs. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本试验采用电子病例报告表(CRF),所有数据通过红帽系统(REDCap)采集和管理。REDCap是免费且功能强大的数据采集、储存和管理的云工具。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The research will utilize an electronic case report form (CRF) and all data will be captured and managed through the RedCap system (REDCap), a free and powerful cloud-based tool for data capture, storage and management. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |